{
    "nct_id": "NCT06550895",
    "official_title": "A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma",
    "inclusion_criteria": "* Documented diagnosis of MM according to the IMWG diagnostic criteria and is defined as a measurable disease at screening\n* Cohort 1: Received at least 3 prior lines of antimyeloma therapy and have undergone greater than or equal to (>=) 1 complete cycle of the therapy\n* Cohort 1: Documented evidence of progression of disease (PD) or failure to achieve a response to the last line of therapy\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1\n* Participant of childbearing potential (POCBP) must have a negative pregnancy test using a highly sensitive Î²-human chorionic gonadotropin (hCG) serum pregnancy test at screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Cohort 1: Prior treatment with chimeric antigen receptor T cell (CAR-T) therapy directed at any target or any prior B cell maturation antigen (BCMA)-directed therapy/prior G protein-coupled receptor family C Group 5 member D (GPRC5D)-directed therapy\n* Cohort 1: Received either of the following: An allogenic stem cell transplant within 6 months before apheresis/first dose of study drug and no immunosuppressive medications administered before the start of study treatment. And secondly, received an autologous stem cell transplant less than (<)12 weeks before apheresis/first dose of study treatment\n* Receive live, attenuated vaccine within 4 weeks of enrollment\n* Toxicity from previous anticancer therapy not resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy\n* Stroke, transient ischemic attack, or seizure within 6 months of signing informed consent form",
    "miscellaneous_criteria": ""
}